Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 11/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 2/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5401957 | 0.89 | ADORA1 (0.66) | ADORA1ADORA2ANOTUMDHFR | |
| SCHEMBL5397339 | 0.85 | ADORA1 (0.57) | ADORA1ADORA2AKMT2AGFER | |
| SCHEMBL5400360 | 0.80 | ADORA1 (0.43) | ADORA1ADORA2ANOTUMCLK1CDC7 | |
| SCHEMBL5397397 | 0.79 | ADORA1 (0.66) | ADORA1ADORA2ARPS6KA3KMT2ACLK1 | |
| SCHEMBL5407262 | 0.79 | AURKA (0.51) | ADORA1NOTUM | |
| SCHEMBL5401943 | 0.79 | ADORA1 (0.47) | ADORA1ADORA2ARPS6KA3CLK1 | |
| SCHEMBL5396690 | 0.78 | AURKA (0.42) | ADORA1NOTUM | |
| SCHEMBL5410470 | 0.78 | ADORA1 (0.65) | ADORA1ADORA2AKMT2ADHFRCLK1 | |
| Dimethylformamide SCHEMBL27599693 | 0.78 | ADORA1 (0.48) | ADORA1ADORA2AKMT2ACLK1GFER | |
| SCHEMBL6997967 | 0.76 | NOTUM (0.38) | ADORA1ADORA2ANOTUMKMT2ACLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363906-B1 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMA (US) | 2015-07-15 | — | — | EP | claimed |
| US-6743791-B2 | ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-01 | — | — | US | claimed |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-15 | — | — | US | claimed |
| EP-1363906-B1 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMA (US) | 2015-07-15 | — | — | EP | disclosed |
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CAO JINGRONG | 2007-11-15 | — | — | US | disclosed |
| US-7253187-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-07 | — | — | US | disclosed |
| US-20040229875-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAPKAPK2 | ADORA1 4421/4885ADORA2A 4397/4885NOTUM 1622/4885 |
| US-20040229875-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | ADORA1 4106/4885ADORA2A 4174/4885NOTUM 3906/4885 |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | ADORA1 4106/4885ADORA2A 4174/4885NOTUM 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.